Graham Doyle: Great, thanks. And hopefully just a quick follow-up. On dry eye on COMET-2, it looks like that primary completion is sort of mid-July, and typically these types of trials could be a couple of months of data cleaning before you would have that in house. Do you guys have to show that tools once you get it typically with other companies in similar Phase III trials if that has been the case. I know you kind of insinuated it would be more like a Q1 ’24 data sharing with the markets? Can you just give us an update on that please?
David Endicott: Yeah, we have actually three studies going on right now and they’re all kind of sequentially finishing over the next, I would say, six months or five months, let’s just say. Most of that data, I think finishes late this year, maybe early next year. And once we have it in-hand and can look at we’ll obviously report out what we’ve got.
Graham Doyle: Super clear. Thanks a lot guys.
Operator: Our next question is from Ryan Zimmerman with BTIG. Please proceed.
Ryan Zimmerman: Good morning and thanks for taking the questions, David and Tim and congrats on the results. Just want to ask a couple following up on the ATIOL space. You guys had laid out and showed investors what you’re working on in adjustables and accommodative lenses in the market or — what you’re working on given what we’re seeing in the market in the US, David, I’m wondering if you’re willing to put some timelines out there in terms of your adjustable and accommodative efforts when we could expect that in the market to maybe fend off some of the competition?
David Endicott: Yeah, we’re not in a position right now where we want to lay out exactly when we’re coming with adjustable and accommodate. As we said at Capital Markets day, it’s late in the plan, it’s just slightly outside the plan. So it’s going to be a while for us to get what we think is a market ready product, and I would say the view we have of course is that we’ve got some terrific lenses with PanOptix and with Vivity. They’re kind of unsurpassed in their ability to create a reading for patients. I understand there are other lenses out there that are kind of working through some of these similar kind of adjustability ideas. But as you know, we haven’t really figured out whether those are really kind of just niche ideas or whether they’re really durable.
My sense of it is that we’ll find that out over the next coming years, but directionally, nobody is really working on the combination of accommodative and adjustable like we are. And I think we’ve probably got the right idea, but it’s going to take some time. I think over the next, I would say, three or four years, the real magic is going to be in getting the diagnostics and getting the procedure tuned in a way that really performs, and I think that’s very likely to happen with our equipment and our lenses. I think we’ve got a very good combination of things that will move the market along in the PCIOL area.
Ryan Zimmerman: Okay, fair enough. And then on guidance for Tim, first half revenue and guidance implies essentially no growth in second half ’23 despite seasonality. And then at the midpoint, it would be a little bit of a decline I believe on revenue. And so, Tim, just wondering kind of what your thoughts are there given what your underlying assumptions are for the market dynamics in the back half of the year?
Tim Stonesifer: Yeah, great question. As we said on the prepared remarks, we expect we’re trending right now towards the higher end of that range. If you look at sort of the first half, Asia ran a little bit up, particularly China. So we’ll see how that plays out over the course of the year. But we’re tracking pretty close to those historical trends. So I would plan on that, and as we gave the guidance, I think we’re trending towards the higher end.
